Aventis to exit rabies vaccine JV with Novartis in India
This article was originally published in Scrip
Aventis Pharma is exiting its rabies vaccine joint venture with Novartis in India.
You may also be interested in...
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.